Literature DB >> 20142924

The declaration of Istanbul on organ trafficking and transplant tourism.

.   

Abstract

Entities:  

Year:  2008        PMID: 20142924      PMCID: PMC2813140          DOI: 10.4103/0971-4065.43686

Source DB:  PubMed          Journal:  Indian J Nephrol        ISSN: 0971-4065


× No keyword cloud information.

Preamble

Organ transplantation, one of the medical miracles of the twentieth century, has prolonged and improved the lives of hundreds of thousands of patients worldwide. The many great scientific and clinical advances of dedicated health professionals, as well as countless acts of generosity by organ donors and their families, have made transplantation not only a life-saving therapy but a shining symbol of human solidarity. Yet these accomplishments have been tarnished by numerous reports of trafficking in human beings who are used as sources of organs and of patient-tourists from rich countries who travel abroad to purchase organs from poor people. In 2004, the World Health Organization, called on member states “to take measures to protect the poorest and vulnerable groups from transplant tourism and the sale of tissues and organs, including attention to the wider problem of international trafficking in human tissues and organs”.1 To address the urgent and growing problems of organ sales, transplant tourism and trafficking in organ donors in the context of the global shortage of organs, a Summit Meeting of more than 150 representatives of scientific and medical bodies from around the world, government officials, social scientists, and ethicists, was held in Istanbul from April 30 to May 2, 2008. Preparatory work for the meeting was undertaken by a Steering Committee convened by The Transplantation Society (TTS) and the International Society of Nephrology (ISN) in Dubai in December 2007. That committee's draft declaration was widely circulated and then revised in light of the comments received. At the Summit, the revised draft was reviewed by working groups and finalized in plenary deliberations. This Declaration represents the consensus of the Summit participants. All countries need a legal and professional framework to govern organ donation and transplantation activities, as well as a transparent regulatory oversight system that ensures donor and recipient safety and the enforcement of standards and prohibitions on unethical practices. Unethical practices are, in part, an undesirable consequence of the global shortage of organs for transplantation. Thus, each country should strive both, to ensure that programs to prevent organ failure are implemented and to provide organs to meet the transplant needs of its residents from donors within its own population or through regional cooperation. The therapeutic potential of deceased organ donation should be maximized not only for kidneys but also for other organs, appropriate to the transplantation needs of each country. Efforts to initiate or enhance deceased donor transplantation are essential to minimize the burden on living donors. Educational programs are useful in addressing the barriers, misconceptions and mistrust that currently impede the development of sufficient deceased donor transplantation; successful transplant programs also depend on the existence of the relevant health system infrastructure. Access to healthcare is a human right but often not a reality. The provision of care for living donors before, during and after surgery–as described in the reports of the international forums organized by TTS in Amsterdam and Vancouver2–4 is no less essential than taking care of the transplant recipient. A positive outcome for a recipient can never justify harm to a live donor; on the contrary, for a transplant with a live donor to be regarded as a success means that both the recipient and the donor have done well. This Declaration builds on the principles of the Universal Declaration of Human Rights.5 The broad representation at the Istanbul Summit reflects the importance of international collaboration and global consensus to improve donation and transplantation practices. The Declaration will be submitted to relevant professional organizations and to the health authorities of all countries for consideration. The legacy of transplantation must not be the impoverished victims of organ trafficking and transplant tourism but rather a celebration of the gift of health by one individual to another.

Definitions

Organ trafficking is the recruitment, transport, transfer, harboring or receipt of living or deceased persons or their organs by means of the threat or use of force or other forms of coercion, of abduction, of fraud, of deception, of the abuse of power or of a position of vulnerability, or of the giving to, or the receiving by, a third party of payments or benefits to achieve the transfer of control over the potential donor, for the purpose of exploitation by the removal of organs for transplantation.6 Transplant commercialism is a policy or practice in which an organ is treated as a commodity, including by being bought or sold or used for material gain. Travel for transplantation is the movement of organs, donors, recipients or transplant professionals across jurisdictional borders for transplantation purposes. Travel for transplantation becomes transplant tourism if it involves organ trafficking and/or transplant commercialism or if the resources (organs, professionals and transplant centers) devoted to providing transplants to patients from outside a country undermine the country's ability to provide transplant services for its own population. National governments, working in collaboration with international and non-governmental organizations, should develop and implement comprehensive programs for the screening, prevention and treatment of organ failure, which include: The advancement of clinical and basic science research; Effective programs, based on international guidelines, to treat and maintain patients with end-stage diseases, such as dialysis programs for renal patients, to minimize morbidity and mortality, alongside transplant programs for such diseases; Organ transplantation as the preferred treatment for organ failure for medically suitable recipients. Legislation should be developed and implemented by each country or jurisdiction to govern the recovery of organs from deceased and living donors and the practice of transplantation, consistent with international standards. Policies and procedures should be developed and implemented to maximize the number of organs available for transplantation, consistent with these principles; The practice of donation and transplantation requires oversight and accountability by health authorities in each country to ensure transparency and safety; Oversight requires a national or regional registry to record deceased and living donor transplants; Key components of effective programs include public education and awareness, health professional education and training, and defined responsibilities and accountabilities for all stakeholders in the national organ donation and transplant system. Organs for transplantation should be equitably allocated within countries or jurisdictions to suitable recipients without regard to gender, ethnicity, religion, or social or financial status. Financial considerations or material gain of any party must not influence the application of relevant allocation rules. The primary objective of transplant policies and programs should be optimal short- and long-term medical care to promote the health of both donors and recipients. Financial considerations or material gain of any party must not override primary consideration for the health and well-being of donors and recipients. Jurisdictions, countries and regions should strive to achieve self-sufficiency in organ donation by providing a sufficient number of organs for residents in need from within the country or through regional cooperation. Collaboration between countries is not inconsistent with national self- sufficiency as long as the collaboration protects the vulnerable, promotes equality between donor and recipient populations, and does not violate these principles; Treatment of patients from outside the country or jurisdiction is only acceptable if it does not undermine a country's ability to provide transplant services for its own population. Organ trafficking and transplant tourism violate the principles of equity, justice and respect for human dignity and should be prohibited. Because transplant commercialism targets impoverished and otherwise vulnerable donors, it leads inexorably to inequity and injustice and should be prohibited. In Resolution 44.25, the World Health Assembly called on countries to prevent the purchase and sale of human organs for transplantation. Prohibitions on these practices should include a ban on all types of advertising (including electronic and print media), soliciting, or brokering for the purpose of transplant commercialism, organ trafficking, or transplant tourism. Such prohibitions should also include penalties for acts—such as medically screening donors or organs, or transplanting organs—that aid, encourage, or use the products of, organ trafficking or transplant tourism. Practices that induce vulnerable individuals or groups (such as illiterate and impoverished persons, undocumented immigrants, prisoners, and political or economic refugees) to become living donors are incompatible with the aim of combating organ trafficking, transplant tourism and transplant commercialism.

Proposals

Consistent with these principles, participants in the Istanbul Summit suggest the following strategies to increase the donor pool and to prevent organ trafficking, transplant commercialism and transplant tourism and to encourage legitimate, life-saving transplantation programs: To respond to the need to increase deceased donation: Governments, in collaboration with health care institutions, professionals, and non-governmental organizations should take appropriate actions to increase deceased organ donation. Measures should be taken to remove obstacles and disincentives to deceased organ donation. In countries without established deceased organ donation or transplantation, national legislation should be enacted that would initiate deceased organ donation and create transplantation infrastructure, so as to fulfill each country's deceased donor potential. In all countries where deceased organ donation has been initiated, the therapeutic potential of deceased organ donation and transplantation should be maximized. Countries with well established deceased donor transplant programs are encouraged to share information, expertise and technology with countries seeking to improve their organ donation efforts. To ensure the protection and safety of living donors and appropriate recognition for their heroic act while combating transplant tourism, organ trafficking and transplant commercialism: The act of donation should be regarded as heroic and honored as such by representatives of the government and civil society organizations. The determination of the medical and psychosocial suitability of the living donor should be guided by the recommendations of the Amsterdam and Vancouver Forums.2–4 Mechanisms for informed consent should incorporate provisions for evaluating the donor's understanding, including assessment of the psychological impact of the process; All donors should undergo psychosocial evaluation by mental health professionals during screening. The care of organ donors, including those who have been victims of organ trafficking, transplant commercialism, and transplant tourism, is a critical responsibility of all jurisdictions that sanctioned organ transplants utilizing such practices. Systems and structures should ensure standardization, transparency and accountability of support for donation. Mechanisms for transparency of process and follow-up should be established; Informed consent should be obtained both for donation and for follow-up processes. Provision of care includes medical and psychosocial care at the time of donation and for any short- and long-term consequences related to organ donation. In jurisdictions and countries that lack universal health insurance, the provision of disability, life, and health insurance related to the donation event is a necessary requirement in providing care for the donor; In those jurisdictions that have universal health insurance, governmental services should ensure donors have access to appropriate medical care related to the donation event; Health and/or life insurance coverage and employment opportunities of persons who donate organs should not be compromised; All donors should be offered psychosocial services as a standard component of follow-up; In the event of organ failure in the donor, the donor should receive: Supportive medical care, including dialysis for those with renal failure, and Priority for access to transplantation, integrated into existing allocation rules as they apply to either living or deceased organ transplantation. Comprehensive reimbursement of the actual, documented costs of donating an organ does not constitute a payment for an organ, but is rather part of the legitimate costs of treating the recipient. Such cost-reimbursement would usually be made by the party responsible for the costs of treating the transplant recipient (such as a government health department or a health insurer); Relevant costs and expenses should be calculated and administered using transparent methodology, consistent with national norms; Reimbursement of approved costs should be made directly to the party supplying the service (such as to the hospital that provided the donor's medical care); Reimbursement of the donor's lost income and out-of-pockets expenses should be administered by the agency handling the transplant rather than paid directly from the recipient to the donor. Legitimate expenses that may be reimbursed when documented include: The cost of any medical and psychological evaluations of potential living donors who are excluded from donation (e.g. because of medical or immunologic issues discovered during the evaluation process); Costs incurred in arranging and effecting the pre-, peri- and post-operative phases of the donation process (e.g. long-distance telephone calls, travel, accommodation and subsistence expenses); Medical expenses incurred for post-discharge care of the donor; Lost income in relation to donation (consistent with national norms).

Participants in the Istanbul Summit

Last nameFirst nameCountry
AbboudOmarSudan
* Abbud-FilhoMarioBrazil
AbdramanovKaldarbekKyrgyzstan
AbdullaSadiqBahrain
AbrahamGeorgiIndia
AbuevaAmihan V.Philippines
AderibigbeAdemolaNigeria
* Al-MousawiMustafaKuwait
AlberuJosefinaMexico
AllenRichard D.M.Australia
Almazan-GomezLynn C.Philippines
AlnonoIbrahimYemen
* AlobaidliAli AbdulkareemUnited Arab Emirates
* AlrukhaimiMonaUnited Arab Emirates
ÁlvarezInésUruguay
AssadLinaSaudi Arabia
AssoungaAlain G.South Africa
BaezYennyColombia
* BagheriAlirezaIran
* BakrMohamed AdelEgypt
BamgboyeEbunNigeria
* BarbariAntoineLebanon
BelghitiJacquesFrance
Ben AbdallahTaiebTunisia
Ben AmmarMohamed SalahTunisia
BosMichaelThe Netherlands
BritzRussellSouth Africa
BudianiDebraUSA
* CapronAlexanderUSA
CastroCristina R.Brazil
* ChapmanJeremyAustralia
ChenZhonghua KlausPeople's Republic of China
CodreanuIgorMoldova
ColeEdwardCanada
CozziEmanueleItaly
* DanovitchGabrielUSA
DavidsRazeenSouth Africa
De BroeMarcBelgium
* De CastroLeonardoPhilippines
* DelmonicoFrancis L.USA
DeraniRaniaSyria
DittmerIanNew Zealand
Domínguez-GilBeatrizSpain
Duro-GarciaValterBrazil
EhtuishEhtuishLibya
El-ShoubakiHatemQatar
EpsteinMiranUnited Kingdom
* FazelIrajIran
Fernandez ZinckeEduardoBelgium
Garcia-GallontRudolfGuatemala
GhodsAhad J.Iran
GillJohnCanada
GlotzDenisFrance
GopalakrishnanGaneshIndia
GracidaCarmenMexico
GrinyoJosepSpain
HaJongwonSouth Korea
* HaberalMehmet A.Turkey
HakimNadeyUnited Kingdom
HarmonWilliamUSA
HasegawaTomonoriJapan
HassanAhmed AdelEgypt
HickeyDavidIreland
HiesseChristianFrance
HongjiYangPeople's Republic of China
HumarInesCroatia
HurtadoAbdiasPeru
Ismail MoustafaWesamEgypt
IvanovskiNinoslavMacedonia
* JhaVivekanandIndia
KahnDelawirSouth Africa
KamelRefaatEgypt
KirpalaniAshokIndia
KirsteGuenterGermany
* KobayashiEijiJapan
KollerJanSlovakia
KranenburgLeoniekeThe Netherlands
* LameireNorbertBelgium
Laouabdia-SellamiKarimFrance
LeiRuipengPeople's Republic of China
* LevinAdeeraCanada
LloverasJosepSpain
LõhmusAleksanderEstonia
LuciolliEsmeraldaFrance
LundinSusanneSweden
LyeWai ChoongSingapore
LynchStephenAustralia
* MaïgaMahamaneMali
Mamzer BruneelMarie-FranceFrance
MaricNicoleAustria
* MartinDominiqueAustralia
* MasriMarwanLebanon
MatamorosMaria A.Costa Rica
MatasArthurUSA
McNeilAdrianUnited Kingdom
MeiserBrunoGermany
MešiEnisaBosnia
MoazamFarhatPakistan
MohsinNabilOman
MorEytanIsrael
MoralesJorgeChile
MunnStephenNew Zealand
MurphyMarkIreland
* NaickerSaraladeviSouth Africa
NaqviS.A. AnwarPakistan
* NoëlLucWHO
ObradorGregorioMexico
OliverosYolandaPhilippines
OnaEnriquePhilippines
OosterleeArieThe Netherlands
OyenOleNorway
PadillaBenitaPhilippines
PratschkeJohannGermany
RahamimovRuthIsrael
RahmelAxelThe Netherlands
ReznikOlegRussia
* RizviS. Adibul HasanPakistan
RobertsLesley AnnTrinidad and Tobago
* Rodriguez-IturbeBernardoVenezuela
RowinskiWojciechPoland
SaeedBassamSyria
SarkissianAshotArmenia
* SayeghMohamed H.USA
Scheper-HughesNancyUSA
SeverMehmet SukruTurkey
* ShaheenFaissal A.Saudi Arabia
SharmaDhananjayaIndia
ShinozakiNaoshiJapan
SimforooshNasserIran
SinghHarjitMalaysia
Sok HeanThongCambodia
SomervilleMargaretCanada
StadtlerMariaUSA
* StephanAntoineLebanon
SuárezJulietteCuba
SuaudeauMsgr. JacquesItaly
SumethkulVasantThailand
TakaharaShiroJapan
ThielGilbert T.Switzerland
* TibellAnnikaSweden
TomadzeGiaGeorgia
* TongMatthew Kwok-LungHong Kong
TsaiDaniel Fu-ChangTaiwan
UriarteRemediosPhilippines
VanrenterghemYves F.C.Belgium
* VathsalaA.Singapore
WeimarWillemThe Netherlands
WiklerDanielUSA
YoungKimberlyCanada
YuldashevUlugbekUzbekistan
ZhaoMinggangPeople's Republic of China

= Members of the Steering Committee. (William Couser, USA, was also a member of the Steering Committee but was unable to attend the Summit.)

  3 in total

1.  The consensus statement of the Amsterdam Forum on the Care of the Live Kidney Donor.

Authors: 
Journal:  Transplantation       Date:  2004-08-27       Impact factor: 4.939

2.  The ethics statement of the Vancouver Forum on the live lung, liver, pancreas, and intestine donor.

Authors:  Timothy L Pruett; Annika Tibell; Abdulmajeed Alabdulkareem; Mahendra Bhandari; David C Cronin; Mary Amanda Dew; Arturo Dib-Kuri; Thomas Gutmann; Arthur Matas; Lisa McMurdo; Axel Rahmel; S Adibul Hasan Rizvi; Linda Wright; Francis L Delmonico
Journal:  Transplantation       Date:  2006-05-27       Impact factor: 4.939

3.  A report of the Vancouver Forum on the care of the live organ donor: lung, liver, pancreas, and intestine data and medical guidelines.

Authors:  Mark L Barr; Jacques Belghiti; Federico G Villamil; Elizabeth A Pomfret; David S Sutherland; Rainer W Gruessner; Alan N Langnas; Francis L Delmonico
Journal:  Transplantation       Date:  2006-05-27       Impact factor: 4.939

  3 in total
  4 in total

1.  Kidneys for Sale? A Commentary on Moeindarbari's and Feizi's Study on the Iranian Model.

Authors:  Frederike Ambagtsheer; Sean Columb; Meteb M AlBugami; Ninoslav Ivanovski
Journal:  Transpl Int       Date:  2022-06-24       Impact factor: 3.842

2.  Organ Procurement and Transplant Equity Among US Residents: The 5% Guideline.

Authors:  Lilia Cervantes; Katherine Rizzolo; David Klassen
Journal:  Am J Kidney Dis       Date:  2021-12-30       Impact factor: 11.072

3.  Long-term renal function in living kidney donors with simple renal cysts: A retrospective cohort study.

Authors:  Madeleine M Waldram; Alvin G Thomas; Yifan Yu; Courtenay M Holscher; Anh Q Nguyen; Samantha E Halpern; Shane Ottman; Abimereki D Muzaale; Macey L Henderson; Krista L Lentine; Fawaz Al Ammary; Daniel C Brennan; Jacqueline M Garonzik-Wang; Dorry L Segev; Allan B Massie
Journal:  Clin Transplant       Date:  2020-08-13       Impact factor: 2.863

4.  Raising awareness of unspecified living kidney donation: an ELPAT view.

Authors:  Lisa Burnapp; Kristof Van Assche; Annette Lennerling; Dorthe Slaats; David Van Dellen; Nizam Mamode; Franco Citterio; Willij Zuidema; Willem Weimar; Frank J M F Dor
Journal:  Clin Kidney J       Date:  2019-06-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.